SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma informs about board meeting

01 Dec 2022 Evaluate
Orchid Pharma has informed that the Board of Directors of the Company, in its meeting held today, December 01, 2022 (commenced at 12.00 pm and concluded at 02:30 pm), has considered and approved the issuance of Equity Shares up to Rs 500 crores including premium through Qualified Institutional Placement under Chapter VI of SEBI ICDR Regulations subject to the approval of the shareholders of the Company. Also enclosed the disclosures in ANNEXURE-A pursuant to aforementioned Regulation read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 09, 2015. This intimation shall also be available on the Company’s website at www.orchidpharma.com.

The above information is a part of company’s filings submitted to BSE.

Orchid Pharma Share Price

570.50 6.40 (1.13%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×